First National Bank of Omaha’s Pacira BioSciences PCRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | – | Sell |
-7,608
| Closed | -$218K | – | 310 |
|
|
2024
Q2 | $218K | Buy |
+7,608
| New | +$218K | 0.01% | 302 |
|
|
2024
Q1 | – | Sell |
-26,014
| Closed | -$878K | – | 337 |
|
|
2023
Q4 | $878K | Buy |
26,014
+2,604
| +11% | +$87.9K | 0.06% | 224 |
|
|
2023
Q3 | $718K | Sell |
23,410
-1,327
| -5% | -$40.7K | 0.05% | 239 |
|
|
2023
Q2 | $991K | Buy |
24,737
+142
| +0.6% | +$5.69K | 0.06% | 221 |
|
|
2023
Q1 | $1M | Buy |
24,595
+254
| +1% | +$10.4K | 0.06% | 218 |
|
|
2022
Q4 | $940K | Sell |
24,341
-800
| -3% | -$30.9K | 0.06% | 224 |
|
|
2022
Q3 | $1.34M | Buy |
25,141
+188
| +0.8% | +$10K | 0.09% | 204 |
|
|
2022
Q2 | $1.45M | Sell |
24,953
-187
| -0.7% | -$10.9K | 0.09% | 198 |
|
|
2022
Q1 | $1.92M | Buy |
25,140
+1,688
| +7% | +$129K | 0.1% | 187 |
|
|
2021
Q4 | $1.41M | Buy |
23,452
+414
| +2% | +$24.9K | 0.07% | 202 |
|
|
2021
Q3 | $1.29M | Buy |
23,038
+14,308
| +164% | +$801K | 0.07% | 213 |
|
|
2021
Q2 | $612K | Hold |
8,730
| – | – | 0.03% | 267 |
|
|
2021
Q1 | $612K | Sell |
8,730
-1,052
| -11% | -$73.7K | 0.03% | 267 |
|
|
2020
Q4 | $585K | Buy |
9,782
+947
| +11% | +$56.6K | 0.03% | 269 |
|
|
2020
Q3 | $531K | Buy |
+8,835
| New | +$531K | 0.03% | 251 |
|